ReviewNature protocols2026
Synthesis of radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Afterglow imaging eliminates the need for real-time excitation light, thereby greatly reducing tissue autofluorescence to achieve highly sensitive bioimaging. However, the clinical translation of existing photoafterglow and sonoafterglow probes developed so far is hampered by their limited tissue penetration. To address this, we recently developed radioafterglow nanoprobes (RANPs) on the basis of a cascade X-ray energy-converting mechanism for cancer-specific imaging and image-guided surgery. RANPs are constructed by co-assembling radioabsorbers, radiosensitizers and radioafterglow substrates into the amphiphilic polymers using the film rehydration method. This approach is rapid (<10 min), offers precise control over the concentration of encapsulated compounds and is highly scalable. Upon X-ray irradiation, RANPs exhibit near-infrared radioafterglow emission (peaked at 788 nm), with long half-life (~4.8 min) and high brightness. These properties enable an excitation depth of the RANPs up to 15 cm, three times deeper than that of photoafterglow. Here we further develop a tumor-specific RANP for precision molecular imaging that activates its radioafterglow signal specifically in the presence of hydrogen peroxide, a key biomarker of the tumor microenvironment. This design enables the ultrasensitive detection (signal-to-background ratio of 169) and surgical resection of small tumors (1 mm
Identifiers
42637845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.